News
INDV
35.82
-0.50%
-0.18
Indivior Pharmaceuticals (INDV) Declares A Special Dividend, Is The Stock Still Cheap?
Simply Wall St · 2d ago
Weekly Report: what happened at INDV last week (0914-0918)?
Weekly Report · 5d ago
Indivior (INDV) Receives a Rating Update from a Top Analyst
TipRanks · 09/18 11:26
Indivior declares $8.13 dividend
Seeking Alpha · 09/17 11:52
Indivior Announces Special Dividend Ahead of Supernus Merger
TipRanks · 09/17 11:47
Indivior declares $8.13 per share special cash dividend
TipRanks · 09/17 11:10
*Indivior Pharmaceuticals Declares Special Cash Div of $8.13/Shr>INDV
Dow Jones · 09/17 11:01
Press Release: Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend
Dow Jones · 09/17 11:00
Indivior accelerates transition from RB manufacturing agreement
TipRanks · 09/15 21:05
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
NASDAQ · 09/14 13:30
Weekly Report: what happened at INDV last week (0907-0911)?
Weekly Report · 09/14 09:23
Weekly Report: what happened at INDV last week (0831-0904)?
Weekly Report · 09/07 09:21
Weekly Report: what happened at INDV last week (0824-0828)?
Weekly Report · 08/31 09:23
Why Indivior Pharmaceuticals (INDV) Is Back In The Spotlight
Simply Wall St · 08/28 09:18
Top Indivior Insider Quietly Ramps Up Stake in Bold New Move
TipRanks · 08/28 02:08
3 Reasons Why Growth Investors Shouldn't Overlook Indivior Pharmaceuticals Inc. (INDV)
NASDAQ · 08/27 16:45
Indivior (INDV) Stock May Trade Below Fair Value On Merger News
Simply Wall St · 08/26 12:22
Weekly Report: what happened at INDV last week (0817-0821)?
Weekly Report · 08/24 09:23
Indivior PLC Earnings Call: Merger, Margins and Growth
TipRanks · 08/23 00:18
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026
NASDAQ · 08/21 16:40
More
Webull provides a variety of real-time INDV stock news. You can receive the latest news about Indivior Pharmaceuticals Inc. through multiple platforms. This information may help you make smarter investment decisions.
About INDV
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.